ALGS - CIK 0001799448
Aligos Therapeutics, Inc. (ALGS) reported revenue of $2.19M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $2.19M | -39.5% |
| FY 2024 | $3.61M | -41.7% |
| FY 2023 | $6.19M | - |
| FY 2022 | $0.00 | - |
| FY 2021 | $0.00 | - |
| FY 2020 | $0.00 | - |
Aligos Therapeutics, Inc. (ALGS) reported revenue of $2.19M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Aligos Therapeutics, Inc.'s revenue grew from $0.00 to $2.19M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.